F7 and hemophilia: The implications of the changing hemophilia landscape for managing inhibitorshave been discussed in updated guidance.98 Product options for managing bleeds in patients with factorinhibitors have been summarized in WFH guidelines.4 Replacement factor therapy may be used for low-responding inhibitors,whereas patients with high-responding inhibitors may require bypassingagents (recombinant activated factor VII or activated prothrombin complexconcentrate, with caveats for those receiving emicizumab prophylaxis) forbreakthrough bleeds and trauma or to cover surgical procedures.